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1. INTRODUCTION {#jcmm14593-sec-0001}
===============

Gastric cancer (GC) is one of the major malignancies with high mortality worldwide.[1](#jcmm14593-bib-0001){ref-type="ref"}, [2](#jcmm14593-bib-0002){ref-type="ref"} Despite significant advances in the study of the pathogenesis of GC, treatments for GC remain limited.[3](#jcmm14593-bib-0003){ref-type="ref"}, [4](#jcmm14593-bib-0004){ref-type="ref"} In addition, recent studies have shown that the pathogenesis behind GC remains largely unknown.[5](#jcmm14593-bib-0005){ref-type="ref"}, [6](#jcmm14593-bib-0006){ref-type="ref"} Therefore, clinical diagnosis and treatment require new predictive biomarkers and their function in the GC to reveal GC benchmarks.

Long non‐coding RNA (lncRNA) is a recently discovered member of the non‐coding RNA family.[7](#jcmm14593-bib-0007){ref-type="ref"} Recently, there is increasing evidence that non‐coding RNAs (ncRNAs) play a key role in human cancer biology.[7](#jcmm14593-bib-0007){ref-type="ref"}, [8](#jcmm14593-bib-0008){ref-type="ref"} These ncRNA molecules over 200 nucleotides in length are named long non‐coding RNAs (lncRNAs) that regulate mRNA translation, transcriptional processes and cell development, differentiation, proliferation and apoptosis.[9](#jcmm14593-bib-0009){ref-type="ref"} There is increasing evidence that lncRNA can be used as a biomarker for the diagnosis and prognosis of various cancers, such as colorectal cancer,[10](#jcmm14593-bib-0010){ref-type="ref"}, [11](#jcmm14593-bib-0011){ref-type="ref"}, [12](#jcmm14593-bib-0012){ref-type="ref"} breast cancer,[11](#jcmm14593-bib-0011){ref-type="ref"}, [12](#jcmm14593-bib-0012){ref-type="ref"} breast cancer,[13](#jcmm14593-bib-0013){ref-type="ref"} liver cancer[14](#jcmm14593-bib-0014){ref-type="ref"} and gastric cancer.[15](#jcmm14593-bib-0015){ref-type="ref"}, [16](#jcmm14593-bib-0016){ref-type="ref"} In addition, in the study of liver metastases from colorectal cancer, it was found that lncRNA UICLM inhibits the expression of miR‐150‐5p by competitive endogenous RNA, thereby promoting liver metastasis of colorectal cancer.[17](#jcmm14593-bib-0017){ref-type="ref"}, [18](#jcmm14593-bib-0018){ref-type="ref"} Long non‐coding RNA can not only regulate gene expression as a competitive endogenous RNA, but also regulate epigenetics by binding to related proteins. For example, lncRNA HOTAIR promotes metastasis of gastric cancer by binding to the epigenetic transcriptional regulator polycomb inhibitor complex 2 (PRC2).[19](#jcmm14593-bib-0019){ref-type="ref"}, [20](#jcmm14593-bib-0020){ref-type="ref"}

In this study, we first found that LINC01303 was significantly up‐regulated in GC tissue and was associated with poor prognosis. Loss and functional gain assays showed that LINC01303 affects GC cell proliferation, migration and invasion by acting as a miR‐101‐3p ceRNA, thereby preventing miR‐101‐3p from binding to the target protein EZH2. Overall, the results indicate that LINC01303 is an important oncogenic regulator in the development of tumours in GC and may be a potential target for clinical diagnosis and treatment of GC.

2. MATERIAL AND METHODS {#jcmm14593-sec-0002}
=======================

2.1. Human samples {#jcmm14593-sec-0003}
------------------

Human GC tissue (n = 30) and matched adjacent non‐tumour tissue (n = 30) were obtained from surgical patients in the Fourth Hospital of Western China. Two pathologists evaluated the histological evaluation of each sample in a double‐blind manner. All GC patients have signed written informed consent, and all procedures are based on the Clinical Research Ethics Committee of the Fourth Hospital of West China.

2.2. Cell lines and treatment {#jcmm14593-sec-0004}
-----------------------------

Human GC cell lines BGC823, SGC 7901, MKN‐45, AGC and immortalized human gastric epithelial cell line GES‐1 were obtained from Cell bank of Chinese Academy of Sciences (Shanghai, China), and no evidence of mycoplasma contamination was detected by using PCR‐based assay test. Cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin in 5% CO~2~ at 37°C.

2.3. Cell proliferation assay {#jcmm14593-sec-0005}
-----------------------------

For the Cell Counting Kit‐8 (CCK‐8) assay, cells were seeded into 96 well plates of 5 × 10^3^ cells/well. CCK‐8 (Dojindo) was added to each well and incubated at 37°C for 2 hours. For colony formation assay, 1 × 10^3^ cells were inoculated without holes in a 6‐well plate, and after 14 days of culture, crystal violet staining was counted.

2.4. Subcutaneous xenograft nude mouse studies {#jcmm14593-sec-0006}
----------------------------------------------

Six‐week BALB/C male nude mice were used for in vivo studies. 5 × 10^6^ cells in 0.2 mL PBS were injected subcutaneously into the dorsal side (n = 3/group). A nude mouse tumour metastasis model was prepared, and a 5 × 10^6^ cell passage was injected into the nude mouse tail vein to the nude mice. Tumour weight was measured after the mice were killed. Tumours were collected and prepared for histological examination.

2.5. Statistical analysis {#jcmm14593-sec-0007}
-------------------------

We performed statistical analysis using Prism 5 and SPSS 18.0 software. Differences between the two groups were assessed using Student\'s *t* test. A *P* value \< .05 was considered to represent a significant difference. The overall survival curve was estimated by the Kaplan‐Meier method and the Cox proportional hazard model. All values are expressed as mean ± SD unless otherwise stated.

3. RESULTS {#jcmm14593-sec-0008}
==========

3.1. LINC01303 is up‐regulated in GC and associated with poor prognosis {#jcmm14593-sec-0009}
-----------------------------------------------------------------------

To investigate the correlation between LINC01303 and human GC, we found that the mRNA expression of LINC01303 in GC tissues was up‐regulated compared to normal gastric tissue by searching public data from the Cancer Genome Atlas (TCGA) database (Figure [1](#jcmm14593-fig-0001){ref-type="fig"}A). We also analysed the mRNA expression levels of LINC01303 in 30 pairs of GC tissues and adjacent non‐tumour tissues by real‐time PCR assay. The results showed that the expression of LINC01303 in GC tissues was significantly higher than that in non‐tumour tissues (Figure [1](#jcmm14593-fig-0001){ref-type="fig"}B, *P* \< .05). To assess the clinical significance of LINC01303 expression in GC, we assessed the association between LINC01303 levels and clinicopathological features. As shown in Table [1](#jcmm14593-tbl-0001){ref-type="table"}, high expression of LINC01303 was associated with patient age (*P* = .018), larger tumour size (*P* = .001), depth of invasion (*P* = .010) and AJCC stage (*P* = .001). We analysed the relationship between the expression level of LINC01303 and the prognosis of patients with GC by Kaplan‐Meier survival. Kaplan‐Meier survival analysis showed that patients with higher levels of LINC01303 had shorter overall survival than patients with lower levels of LINC01303 (Figure [1](#jcmm14593-fig-0001){ref-type="fig"}C). At the same time, LINC01303 was significantly overexpressed in GC cell lines compared to human normal gastric epithelial cells (GES‐1) (Figure [1](#jcmm14593-fig-0001){ref-type="fig"}D). These data indicate that LINC01303 is involved in the pathogenesis of gastric cancer (GC).

![LINC01303 is up‐regulated in GC and associated with poor prognosis. A, LINC01303 levels were increased in GC tissues compared with paired adjacent non‐tumour tissues as determined by The Cancer Genome Atlas. B, LINC01303 levels were increased in GC tissues compared with paired adjacent non‐tumour tissues as determined by real‐time PCR. Data are mean ± SD. n = 30, \**P* \< .05. C, Based on the expression level of LINC01303, the Kaplan‐Meier curve depicts the overall survival curve of 30 patients with gastric cancer. D, Real‐time quantitative PCR was used to analyse the expression of LINC01303 in normal gastric epithelial cell line (GES‐1) and gastric cancer cells. Error bars indicate mean ± SE of the mean. \*\**P *\< .01](JCMM-23-7342-g001){#jcmm14593-fig-0001}

###### 

LINC01303 levels and clinicopathological features in 30 GC patients

  Characteristics                          Total   LINC01303   *P*   
  ---------------------------------------- ------- ----------- ----- -------
  Gender                                                             
  Female                                   13      6           7     1.000
  Male                                     17      8           9     
  Age (y)                                                            
  \>60                                     18      5           13    .018
  ≤60                                      12      2           10    
  Tumour size (cm)                                                   
  \<10                                     14      12          2     .001
  ≥10                                      16      3           13    
  Invasion depth                                                     
  Without Infiltration into Serous layer   20      9           11    .010
  Infiltration into Serous layer           10      1           9     
  AJCC stage                                                         
  I\\II                                    12      8           4     .001
  III\\IV                                  18      2           16    
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3.2. LINC01303 promoted cell proliferation of GC in vitro and in vivo {#jcmm14593-sec-0010}
---------------------------------------------------------------------

To elucidate the effect of LINC01303 on GC cell proliferation, we overexpressed or knocked out LINC01303 to construct SGC7901‐LINC01303 cells stably transfected with BGC823‐shLINC01303 cells for further study (Figure [2](#jcmm14593-fig-0002){ref-type="fig"}A). In order to analyse the effect of knockout or overexpression on the proliferation of gastric cancer cells, we showed that the overexpression of LINC01303 significantly increased the cell proliferation of GC cells by CCK8 and colony formation experiments, while the down‐regulation of LINC01303 significantly inhibited the proliferation of GC cells (Figure [2](#jcmm14593-fig-0002){ref-type="fig"}B,C). At the same time, in order to prove that LINC01303 can also affect the proliferation of gastric cancer in vivo, we further confirmed that LINC01303 significantly promoted the tumorigenicity of GC by subcutaneous xenograft nude mouse model (Figure [2](#jcmm14593-fig-0002){ref-type="fig"}D‐F). Taken together, these data indicate that LINC01303 contributes to the proliferation of GC cells.

![LINC01303 promoted cell proliferation of GC in vitro and in vivo. A, Real‐time quantitative PCR analysis of LINC01303 expression in with the lentivirus SGC 7901‐LINC01303 and with BGC 823‐shLINC01303 for further investigation. B, The CCK8 assay was used to determine the viability of BGC823‐shLINC01303 transfected or SGC7901‐LINC01303 transfected gastric cancer cells. C, Colony formation assays were performed to determine the proliferation of BGC823‐shLINC01303‐transfected or SGC7901‐LINC01303‐transfected gastric cancer cells. D, Stable shLINC01303 knockdown BGC823 cells were used for in vivo assays. E, Represents tumour weight from both groups (n = 3). F, Tumours from two groups of nude mice were shown and measured and showed tumour growth curves after injection of BGC823 cells. Tumour volume was calculated every 4 d. The data represent the mean ± SD from three independent experiments. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](JCMM-23-7342-g002){#jcmm14593-fig-0002}

3.3. LINC01303 accelerates GC cell migration and invasion in vitro and in vivo {#jcmm14593-sec-0011}
------------------------------------------------------------------------------

To clarify whether LINC01303 is capable of modulating GC cell migration and invasion. We performed wound healing and transwell experiments. The results showed that overexpression of LINC01303 significantly promoted the migration and invasion of GC cells (Figure [3](#jcmm14593-fig-0003){ref-type="fig"}B). Conversely, knockdown of LINC01303 significantly inhibited the migration and invasion of GC cells (Figure [3](#jcmm14593-fig-0003){ref-type="fig"}A). Similarly, wound healing experiments further demonstrated that a more efficient wound closure rate was observed in cells overexpressing LINC01303, while a lower wound closure rate was detected in LINC01303 knockdown cells (Figure [3](#jcmm14593-fig-0003){ref-type="fig"}C,D). To demonstrate, in addition, the lung metastasis nude mouse model further confirmed that LINC01303 significantly promoted GC metastasis in vivo. (Figure [3](#jcmm14593-fig-0003){ref-type="fig"}E,F), indicating that LINC01303 promotes GC progression by modulating cell migration and invasion in vitro and in vivo.

![LINC01303 accelerates GC cell migration and invasion in vitro and in vivo*.* A, Matrigel migration and invasion assay of GC cells lenti‐shLINC01303; B, Matrigel migration and invasion assay of GC cells lenti‐LINC01303; C, wound healing assay of GC cells lenti‐shLINC01303; D, wound healing assay of GC cells lenti‐LINC01303. E, F, Representative HE stained sections of lung metastasis nude mice bearing BGC823 control cells or BGC823 shLINC01303 cells (n = 5). The data represent the mean ± SD from three independent experiments. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](JCMM-23-7342-g003){#jcmm14593-fig-0003}

3.4. LINC01303/miR‐101‐3p/EZH2 axis regulates GC progression {#jcmm14593-sec-0012}
------------------------------------------------------------

Then, we found that LINC01303 may act as a sponge to adsorb miR‐101‐3p. Further predictions suggest that miR‐101‐3p may target the 3\'UTR of EZH2. Next, we designed the luciferase reporter gene experiment, as shown in Figure [4](#jcmm14593-fig-0004){ref-type="fig"}A. The results showed that the miR‐101‐3p simulation significantly inhibited the reporter gene activation ability of LINC01303‐WT and EZH2‐WT (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}B,[4](#jcmm14593-fig-0004){ref-type="fig"}). However, the miR‐101‐3p mimic has no inhibitory ability to the mutated luciferase reporter gene of the binding site (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}B,[4](#jcmm14593-fig-0004){ref-type="fig"}). These results suggest that miR‐101‐3p may interact with LINC01303 and EZH2. RT‐PCR results also showed that LINC01303 knockdown increased the expression level of miR‐101‐3p (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}D), while miR‐101‐3p mimic significantly inhibited the expression level of EZH2. (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}E). Western blot confirmed that miR‐101‐3p inhibited EZH2 expression in SGC7901 and BGC823 cells (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}F). At the same time, we have been suggested that LINC01303 may regulate the expression level of EZH2 by competitively adsorbing miR‐101‐3p. To clarify this hypothesis, we knockdown LINC01303 and found that EZH2 expression levels were reduced, while miR‐101‐3p expression levels were up‐regulated (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}G,H). Importantly, we found for the first time that miR‐101‐3p expression levels were negatively correlated with LINC01303 or EZH2 expression levels in GC tissues (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}I,J). In summary, our results demonstrate that LINC01303 regulates the miR‐101‐3p/EZH2 axis in GC. To further confirm the role of LINC01303 in regulating miR‐101‐3p/EZH2 axis in GC progression, we performed experiments using miR‐101‐3p inhibitor and EZH2 siRNA. To confirm transfection efficiency, EZH2 expression was tested in BGC823 cells transfected with the plasmid (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}K). CCK8 and transwell assays were then performed to analyse proliferation, migration and invasion. To elucidate the role of the LINC01303/miR‐101‐3p/EZH2 axis in gastric cancer, we performed experiments using the miR‐101‐3p inhibitor and EZH2 siRNA. EZH2 expression was tested in transfected BGC823 cells (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}K). We then found that LINC01303 silenced inhibition of proliferation (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}L), migration and invasion (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}M,N). The addition of the miR‐101‐3p inhibitor reversed the effect of sh‐LINC01303 (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}L). In addition, the effect of the miR‐101‐3p suppressor was further reversed by knockdown of EZH2 (Figure [4](#jcmm14593-fig-0004){ref-type="fig"}M,N). In summary, the LINC01303/miR‐101‐3p/EZH2 axis plays a key role in regulating GC progression.

![LINC01303/miR‐101‐3p/EZH2 signalling regulates GC progression. A, miR‐101‐3p‐binding sequences in LINC01303 or the 3′‐UTR of EZH2 and mutant sites in LINC01303 or the 3′‐UTR of EZH2. B, C, Luciferase reporter assay showed that the luciferase activity of either LINC01303‐WT or EZH2 3′‐UTR‐WT was inhibited by miR‐101‐3p mimics. D, miR‐101‐3p expression was increased in BGC823 cells after LINC01303 silencing. E, F, EZH2 expression was reduced after transfection with miR‐101‐3p mimics. G, H, LINC01303 regulated EZH2 expression in BGC823 cells through inhibitor miR‐101‐3p. I, The expression of LINC01303 was negatively correlated with miR‐101‐3p expression in GC tissues. J, EZH2 expression was reversely correlated with miR‐101‐3p level in GC tissues. K, Expression of EZH2 was measured in BGC823 cells after transfection with described vectors. L, CCK8 assay was used to analyse cell proliferation. M, N, Transwells assay was exploited to measure migration and invasion in BGC823 cells. The data represent the mean ± SD from three independent experiments. \**P* \< .05. \*\**P* \< .01, \*\*\**P* \< .001](JCMM-23-7342-g004){#jcmm14593-fig-0004}

4. DISCUSSION {#jcmm14593-sec-0013}
=============

There is increasing evidence that long non‐coding RNAs have great potential applications in the diagnosis and treatment of GC.[9](#jcmm14593-bib-0009){ref-type="ref"}, [21](#jcmm14593-bib-0021){ref-type="ref"} In our study, we first demonstrated that the expression of LINC01303 in GC tissues was higher than that in adjacent tissues.

Overall, the mechanism of action of lncRNA is mainly to inhibit the expression of downstream target genes by inhibiting the expression of miRNAs.[7](#jcmm14593-bib-0007){ref-type="ref"}, [22](#jcmm14593-bib-0022){ref-type="ref"} Therefore, the downstream target gene of miRNA is one of the important components of the ceRNA network. For example, LINC01234 inhibits GC cell proliferation mainly through mucus adsorption of miR‐204‐5p, thereby affecting the expression of miR‐204‐5p downstream target genes.[20](#jcmm14593-bib-0020){ref-type="ref"}, [23](#jcmm14593-bib-0023){ref-type="ref"} There are also reports that the long non‐coding RNA NEAT1‐2 adsorbs miR‐106b‐5p through the sponge, thereby up‐regulating the expression of the ATAD2 gene in PTC to promote tumorigenesis and progression.[24](#jcmm14593-bib-0024){ref-type="ref"} LncRNA‐HOXA11‐AS adsorbs miR‐1297 through ceRNA mechanism to promote the proliferation and metastasis of GC cells.[25](#jcmm14593-bib-0025){ref-type="ref"} Therefore, in order to clarify the mechanism by which LINC01303 promotes the development of gastric cancer. We conducted a series of in vitro and in vivo experiments. Overexpression of LINC01303 significantly promoted cell proliferation as demonstrated by CCK‐8 assay and colony formation assays as well as subcutaneous xenograft models in nude mice.

In conclusion, our results indicate that LINC01303 can up‐regulate EZH2 expression as a miR‐101‐3p miRNA sponge, thereby promoting the malignant behaviour of GC cells. Our work suggests that the LINC01303/miR‐101‐3p/EZH2 axis may be a potential target for clinical diagnosis and treatment of GC.
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